ICRF 192 is a weak DNA topoisomerase II ( DNA topoisomerase II ) inhibitor with an IC 50 of 91 μM. ICRF 192 forms an iron-chelating derivative via ring-opening hydrolysis, which can displace Fe 3+ from the Fe 3+ -doxorubicin complex. ICRF 192 is used for studies on the structure-activity relationship of bisdioxopiperazines and the cardiotoxicity of anthracycline drugs.
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Topoisomerase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.